These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22871196)

  • 1. The future of warfarin pharmacogenetics in under-represented minority groups.
    Cavallari LH; Perera MA
    Future Cardiol; 2012 Jul; 8(4):563-76. PubMed ID: 22871196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
    Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
    Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
    Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
    Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of warfarin dose requirements in Hispanics.
    Cavallari LH; Momary KM; Patel SR; Shapiro NL; Nutescu E; Viana MA
    Blood Cells Mol Dis; 2011 Feb; 46(2):147-50. PubMed ID: 21185752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
    Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
    Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population diversity and the performance of warfarin dosing algorithms.
    Suarez-Kurtz G
    Br J Clin Pharmacol; 2011 Sep; 72(3):451-3. PubMed ID: 21575037
    [No Abstract]   [Full Text] [Related]  

  • 14. Warfarin pharmacogenetics: does more accurate dosing benefit patients?
    Eby C
    Semin Thromb Hemost; 2012 Oct; 38(7):661-6. PubMed ID: 23047421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
    Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
    Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
    Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
    Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic determinants of variability in warfarin response after the dose-titration phase.
    Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM
    Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacogenetics of the response to warfarin in Chinese.
    Lam MP; Cheung BM
    Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.